Bisoprolol works by selectively blocking beta-1 adrenergic receptors in the heart. Under normal conditions, adrenaline and noradrenaline bind to these receptors to increase heart rate and the force of heart muscle contraction. By blocking them, bisoprolol slows the heart rate and reduces the force of each heartbeat. This lowers the heart's demand for oxygen and reduces blood pressure, making it easier for a weakened heart to pump blood efficiently in heart failure, and reducing the strain on blood vessels in hypertension.
Developed as part of a rational drug design effort in the late 1970s to create a highly beta-1 selective adrenergic antagonist with balanced pharmacokinetics, avoiding the extreme lipophilicity of propranolol and the pure renal clearance of atenolol.
Bisoprolol emerged from the second generation of beta-blocker development, aiming to improve upon the limitations of early agents like propranolol. While propranolol was non-selective and highly lipophilic (causing central nervous system side effects), and atenolol was highly hydrophilic (relying entirely on renal clearance), bisoprolol was engineered to be highly cardioselective with a unique 50:50 hepatic and renal clearance profile. First patented in the late 1970s and introduced clinically in Europe in the 1980s, it gained United States Food and Drug Administration (FDA) approval in 1992. Its landmark Cardiac Insufficiency Bisoprolol Study II (CIBIS II) trial in 1999 cemented its role in heart failure, demonstrating a significant reduction in mortality and sudden cardiac death in patients with reduced ejection fraction, shifting the paradigm of beta-blocker use from a contraindication in heart failure to a cornerstone of therapy.
Initially developed and approved for the management of essential hypertension and chronic stable angina pectoris, before its profound mortality benefits in chronic heart failure were established in the late 1990s.